期刊
MOLECULAR AND CELLULAR BIOCHEMISTRY
卷 476, 期 6, 页码 2449-2464出版社
SPRINGER
DOI: 10.1007/s11010-021-04099-0
关键词
Aromatase; Aromatase-regulators; Tumor-derived factors; Stromal derived factors; Aromatase-inhibitors (AIs); Combination therapy
类别
资金
- Cancer Prevention and Research Institute of Texas (CPRIT) Award [RR140008]
The regulation of aromatase, an enzyme involved in estrogen biosynthesis, is associated with growth factor signaling and immune response modulation. Aromatase inhibitors (AIs) are used in treating hormone-dependent cancers but the increase in AI-resistance calls for new targeted therapies. Tumor and stromal-derived growth factors and immune cell modulators play key roles in regulating aromatase activity.
The regulation of aromatase, an enzyme involved in the biosynthesis of estrogen in normal and cancer cells, has been associated with growth factor signaling and immune response modulation. The tissue-specific regulatory roles of these factors are of particular importance as local aromatase expression is strongly linked to cancer development/progression and disease outcomes in patients. Therefore, aromatase has become a chemotherapeutic target and aromatase inhibitors (AIs) are used in the clinic for treating hormone-dependent cancers. Although AIs have shown promising results in the treatment of cancers, the emerging increase in AI-resistance necessitates the development of new and improved targeted therapies. This review discusses the role of tumor and stromal-derived growth factors and immune cell modulators in regulating aromatase. Current single-agent and combination therapies with or without AIs targeting growth factors and immune checkpoints are also discussed. This review highlights recent studies that show new connections between growth factors, mediators of immune response, and aromatase regulation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据